These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 2313489)

  • 1. FDA regulations and guidelines.
    Rothschild A
    J Parenter Sci Technol; 1990; 44(1):26-9. PubMed ID: 2313489
    [No Abstract]   [Full Text] [Related]  

  • 2. Foreign establishment registration and listing. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2001 Nov; 66(228):59138-61. PubMed ID: 11776289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A strike against preemption.
    Nat Biotechnol; 2009 May; 27(5):397. PubMed ID: 19430422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reaction of FDA to a fundamental change in the nature of regulations.
    Kennedy D
    J Parenter Drug Assoc; 1979; 33(1):17-20. PubMed ID: 253023
    [No Abstract]   [Full Text] [Related]  

  • 5. A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
    McCabe AR
    Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844
    [No Abstract]   [Full Text] [Related]  

  • 6. FDA user fees and innovation.
    Somberg J
    Am J Ther; 2008; 15(2):97. PubMed ID: 18356626
    [No Abstract]   [Full Text] [Related]  

  • 7. ISO 9000. Policy implications for FDA. Taking the pulse of increasing global use of the ISO series of uniform quality standards by FDA regulated industries.
    Schwemer WL; Lynch MA
    J Parenter Sci Technol; 1993; 47(3):101-18. PubMed ID: 8360802
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmaceuticals and medical devices: FDA oversight.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2009 Jan; ():1-28. PubMed ID: 19297718
    [No Abstract]   [Full Text] [Related]  

  • 9. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 10. The FDA and "privatization"--the drug approval process.
    Rutherford EM
    Food Drug Law J; 1995; 50 Spec():203-25. PubMed ID: 10343044
    [No Abstract]   [Full Text] [Related]  

  • 11. Sandoz sues FDA over delay in first biogeneric approval.
    Fox JL
    Nat Biotechnol; 2005 Nov; 23(11):1327-8. PubMed ID: 16273046
    [No Abstract]   [Full Text] [Related]  

  • 12. Supplements and other changes to an approved application. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2004 Apr; 69(68):18727-67. PubMed ID: 15072041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA considers tightening regulations for direct-to-consumer advertising.
    Vastag B
    J Natl Cancer Inst; 2005 Dec; 97(24):1806-7. PubMed ID: 16368941
    [No Abstract]   [Full Text] [Related]  

  • 14. FDA's role in drug product recalls.
    Crawford SY
    Am J Hosp Pharm; 1991 Dec; 48(12):2595-6. PubMed ID: 1814194
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmaceuticals and medical devices: FDA oversight. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2008 Jan; ():1-18. PubMed ID: 18345557
    [No Abstract]   [Full Text] [Related]  

  • 16. Prescription for the Orphan Drug Act: the impact of the FDA's 1992 regulations and the latest congressional proposals for reform.
    Clissold DB
    Food Drug Law J; 1995; 50(1):125-47. PubMed ID: 10342989
    [No Abstract]   [Full Text] [Related]  

  • 17. Editorial: Some caveats for the FDA.
    Calif Med; 1973 Oct; 119(4):64-5. PubMed ID: 4749314
    [No Abstract]   [Full Text] [Related]  

  • 18. Off-label promotion.
    Somberg J
    Am J Ther; 2006; 13(5):387. PubMed ID: 16988530
    [No Abstract]   [Full Text] [Related]  

  • 19. Dietary supplements: background for dialogue between the industry and the medical profession.
    Friede AI
    Food Drug Law J; 1998; 53(3):413-20. PubMed ID: 10346719
    [No Abstract]   [Full Text] [Related]  

  • 20. Pediatric Research Equity Act.
    J Natl Cancer Inst; 2004 Dec; 96(24):1810. PubMed ID: 15601636
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.